Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 2 years or older, and their biological family members, may be considered for this trial.
- All participants (and a parent or guardian for anyone under 18) must sign a consent form showing they understand the study and its risks before anything begins.
- People who have a confirmed or suspected inherited urologic (urinary/kidney-related) cancer where the responsible gene is already known — for example, von Hippel-Lindau (VHL) or hereditary papillary renal carcinoma (HPRC) — may be considered, along with their biological relatives.
- People who have a confirmed or suspected inherited urologic cancer where the responsible gene has not yet been identified — such as certain hereditary forms of kidney cancers including clear cell, chromophobe, oncocytoma, Type II papillary renal cancer, or Birt Hogg Dube syndrome — may be considered, along with their biological relatives.
- People from families where more than one member has been affected by the same or related cancers, suggesting a possible but unproven genetic cause, may be considered, along with their biological relatives.
- Biological relatives of affected individuals — whether or not they are personally affected by cancer — may be considered for in-person evaluation at the study site (Subject Category A).
- Biological relatives of affected individuals who live far away and are unable to travel to the study site may be considered for participation through local testing and a blood sample (Subject Category B).
- Biological relatives who are enrolled mainly to help with genetic research studies, contributing only a blood sample for DNA analysis, may be considered (Subject Category C).
- People who may be considered under Category A include those with one or more of the following features in a pattern suggesting a hereditary condition: kidney tumours or cysts, certain tumours of the brain or spinal cord, eye growths (retinal angioma), pancreatic tumours or cysts, a type of adrenal gland tumour (pheochromocytoma), certain benign growths in the reproductive system, ear tumours, skin growths or fibrous bumps, a history of spontaneous collapsed lung, lung cysts, thyroid cancer, intestinal polyps with or without bowel cancer, or certain muscle tumours of the skin, uterus, or other tissues.
Who may not be able to join:
- There are no listed exclusion criteria for this trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: W. Marston Linehan, M.D., National Cancer Institute (NCI)
Phone: (240) 760-6247
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Identify and describe as yet unknown or uncharacterized inherited urologic malignant disorders.; Determine the genetic etiology of hereditary urologic malignant disorders in which the gene variation is unknown, by linkage analysis, positional cloning and evaluation of candidate genes.; Correlate specific mutations and their associated protein domains with disease phenotypic expression based on parameters including presenting age, clinical manifestations, histopathology and rate of recurrence.; Characterize the natural and clinical histories of inherited urologic malignant disorders.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.